Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.

Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis.

BACKGROUND: Gastric carcinoma (GC) is one of the highest cancer-mortality diseases with a high incidence rate in Asia. For surgically unfit but medically fit patients, palliative chemotherapy is the main treatment. The chemotherapy regimen of docetaxel, cisplatin and 5-fluorouracil (DCF) has been us...

Full description

Bibliographic Details
Main Authors:	Xiao-Long Chen, Xin-Zu Chen, Chen Yang, Yan-Biao Liao, He Li, Li Wang, Kun Yang, Ka Li, Jian-Kun Hu, Bo Zhang, Zhi-Xin Chen, Jia-Ping Chen, Zong-Guang Zhou
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2013-01-01
Series:	PLoS ONE
Online Access:	http://europepmc.org/articles/PMC3617226?pdf=render

Similar Items

Liposomal paclitaxel versus docetaxel in induction chemotherapy using Taxanes, cisplatin and 5-fluorouracil for locally advanced nasopharyngeal carcinoma
by: Sai-Lan Liu, et al.
Published: (2018-12-01)

Modified DCF (Docetaxel, Cisplatin and 5-fluorouracil) chemotherapy is effective for the treatment of advanced rectal squamous cell carcinoma
by: Laure Hervé, et al.
Published: (2022-11-01)

Impact of preoperative docetaxel, cisplatin, and 5-fluorouracil (DCF) therapy on degree of malignant esophageal stenosis
by: Takahisa Yamaguchi, et al.
Published: (2023-08-01)

Assessment of neoadjuvant chemotherapy with docetaxel, cisplatin, and fluorouracil in patients with oral cavity cancer
by: Jin Ye Fu, et al.
Published: (2023-02-01)

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma
by: Ting Jin, et al.
Published: (2019-04-01)

Induction chemotherapy regimen of docetaxel plus cisplatin versus docetaxel, cisplatin plus fluorouracil followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: Preliminary results of an open-label, noninferiority, multicentre, randomised, controlled phase 3 trial
by: Yan Wang, et al.
Published: (2022-11-01)

Relationship between the Expression of the Thymidylate Synthase and the Prognosis of Gastric Cancer Patients Treated with Combinational Chemotherapy Regimen Including Fluorouracil, Docetaxel and Cisplatin
by: Mozaffar Aznab, et al.
Published: (2020-07-01)

Concurrent chemotherapy using taxane plus cisplatin cisplatin alone in high-risk nasopharyngeal carcinoma patients with suboptimal response to induction chemotherapy
by: Ya-Ni Zhang, et al.
Published: (2023-06-01)

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma
by: Stefano Kim, et al.
Published: (2022-08-01)

Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD groups (Epitopes-HPV02 study)
by: Stefano Kim, et al.
Published: (2017-08-01)

Induction chemotherapy with dose-modified docetaxel, cisplatin, and 5-fluorouracil in Asian patients with borderline resectable or unresectable head and neck cancer
by: Hung-Ming Wang, et al.
Published: (2017-03-01)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
by: Ryutaro Onaga, et al.
Published: (2023-06-01)

Ganoderma spore lipid ameliorates docetaxel, cisplatin, and 5-fluorouracil chemotherapy-induced damage to bone marrow mesenchymal stem cells and hematopoiesis
by: Haohui Lin, et al.
Published: (2024-04-01)

Long-Term Survival of Patients With Chemotherapy-Naïve Metastatic Nasopharyngeal Carcinoma Receiving Cetuximab Plus Docetaxel and Cisplatin Regimen
by: Mengping Zhang, et al.
Published: (2020-06-01)

Preoperative chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal carcinosarcoma: a case report and review of the literature
by: Tomoko Yoshimoto, et al.
Published: (2018-02-01)

Dramatic response to modified docetaxel, cisplatin, and fluorouracil chemotherapy after immunotherapy in a patient with refractory metastatic anal cancer
by: Faisal Shahjehan, et al.
Published: (2019-09-01)

The efficacy and safety of 5-fluorouracil/cisplatin/vincristine as a multi-agent chemotherapy regimen in gestational trophoblastic neoplasia
by: Lu Wang, et al.
Published: (2023-10-01)

Effectiveness of neoadjuvant chemotherapy with a docetaxel, cisplatin, and S-1 (DCS) regimen for T4b gastric cancer
by: Vo Duy Long, et al.
Published: (2024-12-01)

Efficacy of docetaxel, cisplatin, and 5-fluorouracil as an induction chemotherapy in oral squamous cell carcinoma in a tertiary hospital in Saudi Arabia
by: Mohammad Alessa, et al.
Published: (2024-01-01)

Outcomes of esophagectomy after chemotherapy with biweekly docetaxel plus cisplatin and fluorouracil for advanced esophageal cancer: a retrospective cohort analysis
by: Yuji Akiyama, et al.
Published: (2018-07-01)

Evaluation of a docetaxel-cisplatin-fluorouracil-Au complex in human oral carcinoma cell line
by: Wannisa Khamaikawin, et al.
Published: (2023-12-01)

Cost-effectiveness analysis of serplulimab in combination with cisplatin plus 5-fluorouracil chemotherapy compared to cisplatin plus 5-fluorouracil chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma in China
by: Ying-Tao Lin, et al.
Published: (2023-11-01)

Low-cost outpatient chemotherapy regimen of cisplatin, 5-fluorouracil and leucovorin for advanced head and neck and esophageal carcinomas
by: Vanessa de Carvalho Fabrício, et al.

Docetaxel and cisplatin induction chemotherapy with or without fluorouracil in locoregionally advanced head and neck squamous cell carcinoma: A real-world data study
by: Matheus Yung Perin, et al.
Published: (2025-05-01)

Urachal Carcinoma with Choroidal, Lung, Lymph Node, Adrenal, Mammary, and Bone Metastases and Peritoneal Carcinomatosis Showing Partial Response after Chemotherapy Treatment with a Modified Docetaxel, Cisplatin and 5-Fluorouracil Regimen
by: Kathleen Dekeister, et al.
Published: (2016-04-01)

Delirium and seizures in a patient with head-and-neck squamous cell carcinoma on docetaxel, cisplatin, and 5-fluorouracil
by: Satvik Khaddar, et al.
Published: (2019-01-01)

Comparison of a Concurrent Fluorouracil-Based Regimen and a Taxane-Based Regimen Combined with Radiotherapy in Elderly Patients with Esophageal Squamous Cell Carcinoma
by: Chunyue Huang, et al.
Published: (2020-03-01)

Long-term results of locoregionally advanced nasopharyngeal carcinoma treated with cisplatin and 5-fluorouracil induction chemotherapy with or without docetaxel in young and middle aged adults
by: Yuming Zheng, et al.
Published: (2025-03-01)

ATR activated by EB virus facilitates chemotherapy resistance to cisplatin or 5-fluorouracil in human nasopharyngeal carcinoma
by: Zhang B, et al.
Published: (2019-01-01)

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
by: Hui Jiang, et al.
Published: (2023-09-01)

Cell death in cancer chemotherapy using taxanes
by: Ana P. Xu, et al.
Published: (2024-01-01)

The efficiency of liposomal paclitaxel versus docetaxel in neoadjuvant chemotherapy with the TPF regimen for locally advanced nasopharyngeal carcinoma: a retrospective study
by: Zhi Yang, et al.
Published: (2024-10-01)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
by: Eun Kyo Joung, et al.
Published: (2021-01-01)

Efficacy of cinobufacini capsule combined with docetaxel plus cisplatin chemotherapy for the treatment of non-small cell lung cancer
by: LI Juan, LI Xiaofeng, XU Shengzhi, TANG Kai
Published: (2024-02-01)

The Acute Toxicities and Efficacy of Concurrent Chemotherapy With Docetaxel Plus Cisplatin, or Docetaxel, or Cisplatin and Helical Tomotherapy in Patients With Locoregionally Advanced Nasopharyngeal Carcinoma: A Randomized Single-Center Phase II Trial
by: Yanrong Luo MD, et al.
Published: (2022-06-01)

Neoadjuvant chemotherapy outcome with taxane-based versus non-taxane protocols in gastric cancer
by: Shirin Kianersi, et al.
Published: (2023-01-01)

Use of a multi-drug regimen gemcitabine, 5-fluorouracil, irinotecan, cisplatin, bevacizumab, docetaxel, and cyclophosphamide (GFIP/BDC) for heavily pretreated relapsed epithelial ovarian, fallopian tube and primary peritoneal cancer
by: Samantha Cohen, et al.
Published: (2019-04-01)

Efficacy and safety of FLOT regimen vs DCF, FOLFOX, and ECF regimens as perioperative chemotherapy treatments for resectable gastric cancer patients; a report from the middle east
by: Pegah Farrokhi, et al.
Published: (2022-01-01)

A Real-World Comparison Between Adjuvant Docetaxel with Cyclophosphamide (TC) and Anthracycline–Taxane Chemotherapy in Early HER-2 Negative Breast Cancer
by: Danilo Giffoni de Mello Morais Mata, et al.
Published: (2024-12-01)

DCF–VQA: Counterfactual Structure Based on Multi–Feature Enhancement
by: Yang Guan, et al.
Published: (2024-09-01)